Zentalis Pharmaceuticals Llc (ZNTL)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$2.24

-0.08 (-3.45%)

Market Cap: $227.64M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

42%(11/26)

Avg Surprise

-17.38%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.55

Range$-0.63 - $-0.46

7 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate DriftChange to current

90d ago$-0.49-12.6%

60d ago$-0.49-12.0%

30d ago$-0.58+4.9%

7d ago$-0.58+4.9%

Current$-0.55

Revenue Consensus

Range$0 - $0

9 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.47

Range$-0.84 - $0.18

8 analysts

Revenue Consensus

Range$0 - $0

9 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.47	$-0.84 - $0.18	-	-	8	-	-
Sep 30, 2026Sep 26EST	-	$-0.55	$-0.63 - $-0.46	-	-	7	No revisions (30d)	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-0.59	$-0.45	$-0.61 - $-0.30	-31.11%	Miss	8	No revisions (30d)	-59.5%
Mar 31, 2026Mar 26 Reported May 12, 2026Reported May 12	$-0.50	$-0.47	$-0.50 - $-0.46	-7.43%	Miss	3	0 1 30d	+24.9%
Dec 31, 2025Dec 25 Reported Mar 26, 2026Reported Mar 26	$-0.49	$-0.61	$-1.80 - $-0.25	+19.67%	Beat	7	3 0 30d	+20.2%
Sep 30, 2025Sep 25 Reported Nov 10, 2025Reported Nov 10	$-0.37	$-0.48	$-0.57 - $-0.38	+22.92%	Beat	7	5 1 30d	+33.9%
Jun 30, 2025Jun 25 Reported Aug 6, 2025Reported Aug 6	$-0.37	$-0.52	$-0.81 - $-0.43	+28.85%	Beat	7	4 1 30d	+70.2%
Mar 31, 2025Mar 25 Reported May 14, 2025Reported May 14	$-0.67	$-0.61	$-0.69 - $-0.52	-9.84%	Miss	7	0 2 30d	-578.6%
Dec 31, 2024Dec 24 Reported Mar 26, 2025Reported Mar 26	$-0.61	$-0.68	$-0.99 - $-0.47	+9.96%	Beat	10	4 0 30d	+34.0%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.56	$-0.87	$-0.99 - $-0.81	+35.63%	Beat	9	No revisions (30d)	+29.1%
Jun 30, 2024Jun 24 Reported Aug 9, 2024Reported Aug 9	$-1.24	$-0.83	$-0.98 - $-0.47	-49.40%	Miss	11	No revisions (30d)	+33.0%
Mar 31, 2024Mar 24 Reported May 7, 2024Reported May 7	$0.14	N/A	-	+118.92%	Beat	10	No revisions (30d)	+113.1%
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$-0.93	$-0.92	$-1.54 - $-0.61	-1.09%	Miss	11	No revisions (30d)	-1.1%
Sep 30, 2023Sep 23 Reported Nov 6, 2023Reported Nov 6	$-0.79	$-0.94	$-1.24 - $-0.76	+15.96%	Beat	10	2 0 30d	+17.7%
Jun 30, 2023Jun 23 Reported Aug 9, 2023Reported Aug 9	$-1.85	$-1.02	$-1.15 - $-0.90	-81.37%	Miss	10	No revisions (30d)	-38.1%
Mar 31, 2023Mar 23 Reported May 10, 2023Reported May 10	$-1.07	$-1.03	$-1.44 - $-0.87	-3.88%	Miss	9	No revisions (30d)	+18.3%
Dec 31, 2022Dec 22 Reported Mar 1, 2023Reported Mar 1	$-0.92	$-1.06	$-1.67 - $-0.93	+13.21%	Beat	11	No revisions (30d)	+17.1%
Sep 30, 2022Sep 22 Reported Nov 9, 2022Reported Nov 9	$-0.96	$-1.19	$-1.41 - $-1.01	+19.33%	Beat	9	No revisions (30d)	-966.7%
Jun 30, 2022Jun 22 Reported Aug 9, 2022Reported Aug 9	$-1.34	$-1.20	$-1.32 - $-1.02	-11.67%	Miss	9	1 0 30d	+0.0%
Mar 31, 2022Mar 22 Reported May 5, 2022Reported May 5	$-1.31	$-1.20	$-1.39 - $-1.08	-9.17%	Miss	10	2 0 30d	-5.6%
Dec 31, 2021Dec 21 Reported Feb 24, 2022Reported Feb 24	$-1.11	$-1.49	$-1.59 - $-1.30	+25.50%	Beat	7	No revisions (30d)	-9.9%
Sep 30, 2021Sep 21 Reported Nov 10, 2021Reported Nov 10	$-0.09	N/A	-	+92.80%	Beat	6	2 0 30d	+90.1%
Jun 30, 2021Jun 21 Reported Aug 12, 2021Reported Aug 12	$-1.34	$-1.16	$-1.34 - $-0.93	-15.52%	Miss	6	No revisions (30d)	-71.8%
Mar 31, 2021Mar 21 Reported May 17, 2021Reported May 17	$-1.24	$-0.91	$-1.06 - $-0.86	-36.26%	Miss	5	1 0 30d	+56.9%
Dec 31, 2020Dec 20 Reported Mar 25, 2021Reported Mar 25	$-1.01	$-0.95	$-1.16 - $-0.66	-6.32%	Miss	5	No revisions (30d)	-
Sep 30, 2020Sep 20 Reported Nov 9, 2020Reported Nov 9	$-0.91	$-0.76	$-0.81 - $-0.72	-19.74%	Miss	3	No revisions (30d)	-
Jun 30, 2020Jun 20 Reported Aug 13, 2020Reported Aug 13	$-0.78	$-0.49	$-0.58 - $-0.41	-59.18%	Miss	3	1 0 30d	-
Mar 31, 2020Mar 20 Reported Apr 6, 2020Reported Apr 6	$-2.88	$-0.47	$-0.96 - $-0.47	-512.77%	Miss	4	No revisions (30d)	-

Key Metrics

Valuation
P/E Ratio	-1.15	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-66.70%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	4.82x	Quick Ratio	4.82x
Trading Statistics
Beta	1.94	Avg Volume	1.36M
52-Week High	$6.95	52-Week Low	$1.21

Technical Indicators Dashboard

Moving Averages

SMA 10$2.52

SMA 20$2.67

SMA 50$3.36

SMA 200$3.47

EMA 10$2.49

EMA 20$2.71

EMA 50$3.21

EMA 200$3.28

MACD

Line: -0.30Signal: -0.30Hist: 0.00

ADX

ADX: 36.6+DI: 13.2-DI: 34.6

Aroon & PSAR

Aroon UpN/A

Aroon Down100.0

PSAR$2.78

Bollinger Bands

Upper Band$3.14

Lower Band$2.20

%B Position3503%(Upper)

Band Width0.04

RSI (14-Day)

Oversold

28.9

Momentum Oscillators

Stoch %K3.2

Stoch %D9.8

Williams %R-96.0

ROC (10d)-14.0%

Momentum-0.36

CCI (20d)-157.8

MFI (14d)46.7

Volatility Measures

ATR (14d)$0.19(8.5%)

StdDev (20d)0.23

Hist Vol68.6%(High)

Volume Flow

VWAP$2.28

OBV67.4M

AD Line41.9M

CMF (20d)-0.175

Volume Metrics

Avg Vol (20d)1.4M

Vol Ratio1.5x

VWMA (20d)$2.67

Pivot Points

R3$2.56

R2$2.51

R1$2.41

Pivot Point$2.36

S1$2.26

S2$2.21

S3$2.11

Advanced Oscillators

TSI-36.87

Ultimate Osc33.9

KST-266.79

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$26.86M	$0	$0	$40.56M	$2.10M	$0
Cost of Revenue	$0	$0	$157,000	$0	$0	$0	$317,000	$0	$0	$0	$337,000	$0
Gross Profit	$0	$0	$-157,000	$0	$0	$0	$26.86M	$0	$0	$40.56M	$1.77M	$0

Operating Expenses	$44.39M	$37.85M	$37.39M	$33.73M	$36.06M	$45.62M	$76.71M	$51.43M	$65.15M	$65.33M	$67.92M	$62.72M
R&D	$35.16M	$28.72M	$29.49M	$22.95M	$27.61M	$27.25M	$32.97M	$36.82M	$48.39M	$49.59M	$51.56M	$46.77M
SG&A	$9.23M	$9.14M	$7.91M	$10.78M	$8.45M	$10.58M	$40.01M	$14.61M	$16.76M	$15.74M	$16.36M	$15.95M
Operating Income	$-44,391,000	$-37,855,000	$-37,393,000	$-33,734,000	$-36,058,000	$-45,623,000	$-49,849,000	$-51,432,000	$-65,148,000	$-24,765,000	$-67,922,000	$-62,718,000

Interest Income	$2.24M	$0	$0	$0	$0	$-2,656,000	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$2.66M	$0	$0	$22.86M	$0	$0	$0
Income Before Tax	$-42,148,000	$-35,232,000	$-34,774,000	$-26,691,000	$-26,874,000	$-48,279,000	$-47,677,000	$-40,185,000	$-88,011,000	$10.18M	$-61,074,000	$-55,509,000
Income Tax Expense	$138,000	$120,000	$442,000	$0	$0	$0	$-205,000	$-27,000	$266,000	$143,000	$-135,000	$31,000

Net Income	$-42,286,000	$-35,352,000	$-35,216,000	$-26,691,000	$-26,874,000	$-48,279,000	$-47,472,000	$-40,158,000	$-88,277,000	$10.04M	$-60,939,000	$-55,540,000

EBITDA	$-44,287,000	$-35,305,000	$-35,048,000	$-27,048,000	$-27,495,000	$-46,395,000	$-48,757,000	$-41,509,000	$-89,880,000	$7.74M	$-65,292,000	$-57,280,000
EBIT	$-44,391,000	$-35,232,000	$-34,774,000	$-26,691,000	$-26,874,000	$-45,623,000	$-47,677,000	$-40,185,000	$-88,011,000	$10.18M	$-61,074,000	$-55,509,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about ZNTL

News

Leerink raised its target to USD 8 for Zentalis Pharmaceuticals stock

Leerink Partners has raised its price target for Zentalis Pharmaceuticals (ZNTL) stock to USD 8.00, upgrading its rating from Market Perform to Outperform. This adjustment follows Zentalis's reported USD 0.59 GAAP loss...

ad-hoc-news.de•Oct 15, 2026 8:32 PM ET10/15/26•Somewhat-Bullish

Certain Common Stock of Zentalis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026.

Certain common stock of Zentalis Pharmaceuticals, Inc. are subject to a lock-up agreement ending on October 13, 2026. This agreement restricts the company, its directors...

www.marketscreener.com•Oct 12, 2026 8:42 PM ET10/12/26•Neutral

ZNTL - Late Stage Ovarian Cancer Trials And Extended Cash Runway Will Support Future Upside Potential

Zentalis Pharmaceuticals (ZNTL) is positioned to advance its drug azenosertib through late-stage development for platinum-resistant ovarian cancer...

Simply Wall Street•Oct 8, 2026 2:41 PM ET10/8/26•Bullish

Zentalis Pharmaceuticals stock fell 3.96 percent as target doubled

Zentalis Pharmaceuticals (ZNTL) saw its stock price fall by 3.96% despite Leerink Partners doubling its price target from $4.00 to $8.00 based on the potential of its investigational drug...

AD HOC NEWS•Oct 6, 2026 10:29 PM ET10/6/26•Neutral

Zentalis Pharmaceuticals stock gains 10.32 percent after Leerink upgrade

Zentalis Pharmaceuticals (ZNTL) stock gained 10.32% to USD 2.78 after Leerink Partners upgraded its rating to Outperform with an USD 8.00 price target. The upgrade reflects Leerink's focus on Zentalis' investigational...

AD HOC NEWS•Oct 6, 2026 8:51 AM ET10/6/26•Bullish

ZNTL Valuation and Fair Value

P/E: -1.1x
P/B: 1.1x

See GNG's fair value

ZNTL Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -66.7%

ZNTL Competitors

Company	Ticker
Electromed Inc	ELMD
Sol Gel Technologies Ltd	SLGL
Lineage Cell Therapeutics Inc	LCTX
Greenwich Lifesciences Inc	GLSI
High Tide Inc	HITI
Spok Holdings Inc	SPOK
Immuneering Corp	IMRX
SIGA Technologies Inc	SIGA

Sector: Healthcare

ZNTL Analyst Ratings

Consensus: Buy
Analysts: 11
Strong Buy: 0
Buy: 6
Hold: 5
Sell: 0
Strong Sell: 0

ZNTL Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 8.6%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.55
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 0 down

Frequently Asked Questions About ZNTL

Does ZNTL pay dividends?

Zentalis Pharmaceuticals Llc (ZNTL) does not currently pay a regular dividend.

What is ZNTL's market cap?

Zentalis Pharmaceuticals Llc (ZNTL) has a market capitalization of $227.64M with a current stock price of $2.24.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In